Press

PSYC Corporation (OTC Pink Market: PSYC), parent company to Spotlight Media Corporation (“SMC” or the “wholly owned subsidiary”), a multimedia leader for all things psychedelics including the emerging medicinal psychedelics market sector, is pleased to provide shareholders with an update on its Bonfire community platform, which is scheduled to relaunch May 1st with several new features and a revamped business model that, according to the Company, is more effectively suited for monetization, growth, and scalability.  In late Q4 of last year, Management agreed to pause any ongoing development with Bonfire following a market test of the platform that ran for the previous…

Sunstone Therapies, a leader in the development of clinical trials and the delivery of psychedelic-assisted therapy in the medical setting, today announces the publication of positive phase 2 data, assessing the effect of psilocybin therapy for patients with cancer and major depression disorder (MDD), in JAMA Oncology. The publication is accessible here. Psilocybin therapy is an approach being investigated for the treatment of mental health challenges, including depression. It combines the pharmacological effects of psilocybin, a naturally occurring psychoactive substance, with psychological support. The study was a phase 2, single-center, fixed-dose, open-label study in 30 patients with curable and incurable cancer….

Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched a new client website at www.numinus.com as part of its branding strategy to align all wellness clinics under the Numinus brand. “Our new website serves as a key connection point to our brand and an extension of our in-clinic services, further supporting our clients throughout their journey with Numinus.Our clients’ wellbeing is our number one priority, and an enhanced digital experience, including easier navigation and more efficient appointment booking tools, should allow us to provide greater…

 Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three and six months ended February 28, 2023 (“Q2 2023” and “first six months”). “We are excited about our recently announced training and licensing growth initiatives, which position Numinus as a clear leader in delivering and supporting psychedelic-assisted therapies – and contribute to much needed clinical infrastructure for a sector that is on the verge of significant expansion. As we believe that access to these therapies is pending with regulatory reform, the development of clinical…

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). This Phase 1 open-label study is designed to assess the safety, tolerability, and pharmacokinetic profile of 60mg, 90mg and 120mg of PCN-101 delivered subcutaneously as compared to 60mg of PCN-101 delivered intravenously (IV). The trial will enroll approximately 16 healthy volunteers across the four cohorts and is expected to be completed in the middle of 2023. In January 2023, atai announced results from the…